Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MDxHealth (MDXH) Cash from Investing Activities (2021 - 2025)

Historic Cash from Investing Activities for MDxHealth (MDXH) over the last 4 years, with Q3 2025 value amounting to -$775000.0.

  • MDxHealth's Cash from Investing Activities fell 586153.85% to -$775000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.6 million, marking a year-over-year decrease of 119109.16%. This contributed to the annual value of -$1.6 million for FY2024, which is 5838.21% up from last year.
  • As of Q3 2025, MDxHealth's Cash from Investing Activities stood at -$775000.0, which was down 586153.85% from -$19.6 million recorded in Q2 2025.
  • In the past 5 years, MDxHealth's Cash from Investing Activities ranged from a high of $13000.0 in Q1 2025 and a low of -$19.6 million during Q2 2025
  • For the 4-year period, MDxHealth's Cash from Investing Activities averaged around -$2.5 million, with its median value being -$242000.0 (2021).
  • Examining YoY changes over the last 5 years, MDxHealth's Cash from Investing Activities showed a top increase of 586153.85% in 2025 and a maximum decrease of 586153.85% in 2025.
  • Quarter analysis of 4 years shows MDxHealth's Cash from Investing Activities stood at -$232000.0 in 2021, then crashed by 85.78% to -$431000.0 in 2022, then soared by 46.87% to -$229000.0 in 2024, then plummeted by 238.43% to -$775000.0 in 2025.
  • Its last three reported values are -$775000.0 in Q3 2025, -$19.6 million for Q2 2025, and $13000.0 during Q1 2025.